leadf
logo-loader
viewAdalta Ltd

AdAlta targeting human trials for lead i-body fibrosis candidate in under a year

AdAlta Ltd (ASX: 1AD) CEO Sam Cobb speaks to Proactive Investors about the biotech's i-body technology platform and pipeline of i-bodies; including its lead candidate for treating fibrotic diseases, in particular Idiopathic Pulmonary Fibrosis, AD-214.

A phase I human study is expected to begin in January 2020.

Quick facts: Adalta Ltd

Price: 0.165 AUD

ASX:1AD
Market: ASX
Market Cap: $40.45 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Adalta Ltd named herein, including the promotion by the Company of Adalta Ltd in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Tony Locantro welcomes Eagle Mountain Mining's new high grade copper hit

Alto Capital's Tony Locantro speaks to Proactive's Andrew Scott following the news by Eagle Mountain Mining Ltd (ASX:EM2) that its first hole in the northern area of the Oracle Ridge Mine Project has intersected high grade copper and silver mineralisation. Locantro also discusses the news this...

4 days, 16 hours ago

2 min read